We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
RegeneRX Biopharmaceuticals Inc (CE) | USOTC:RGRX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0014 | 0.00 | 01:00:00 |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | |
|
| | ||
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 13 | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | |
|
| | ||
| | | | | 15 | | | |
| | | |
|
| | ||
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | |
|
| | ||
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| PROXY CARD | | | | | | | |
| ANNEX A | | | | | | | |
Name
|
| |
Age
|
| |
Principal Occupation/Position Held
|
| |
Director
since |
|
Allan L. Goldstein
|
| | 83 | | | Emeritus Professor & Former Chairman, Department of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Sciences; Founder, Chairman of the Board and Chief Scientific Advisor of the Company | | |
1982
|
|
J.J. Finkelstein | | | 69 | | | President and Chief Executive Officer of the Company | | |
2002
|
|
Joseph C. McNay | | | 87 | | | Chairman, Chief Investment Officer and Senior Portfolio Manager, Essex Investment Management Company | | |
1987
|
|
Mauro Bove | | | 66 | | | SVP Corporate & Business Development, Zhaoke Ophthamology Ltd. | | |
2004
|
|
R. Don Elsey | | | 68 | | | Advisor to the CEO of Lyra Therapeutics, a private therapeutic company | | |
2010
|
|
Alessandro Noseda
|
| | 63 | | | CSO of Leadiant Biosciences S.p.A. | | |
2019
|
|
Name
|
| |
Audit
|
| |
Compensation
|
| ||||||
R. Don Elsey
|
| | | | X | | | | | | X* | | |
Joseph McNay
|
| | | | X* | | | | | | X | | |
Mauro Bove
|
| | | | | | | | | | X | | |
Alessandro Noseda
|
| | | | | | | | | | X | | |
Total meetings in fiscal 2020
|
| | | | 4 | | | | | | 1 | | |
| | |
2020
|
| |
2019
|
| ||||||
Audit fees
|
| | | $ | 90,000 | | | | | $ | 90,000 | | |
Tax fees(1)
|
| | | $ | 14,125 | | | | | $ | 15,000 | | |
Total Fees
|
| | | $ | 104,125 | | | | | $ | 105,000 | | |
| | |
Beneficial Ownership(1)
|
| ||||||||||||
Beneficial Owner
|
| |
Number of Shares
|
| | | | |
Percent of Total
|
| ||||||
5% Stockholders: | | | | | | | | | | | | | | | | |
Entities affiliated previously affiliated with Essetifin S.p.A., Via Sudafrica, 20, Rome, Italy 00144
|
| | | | 55,271,189(2) | | | | | | | | | 34.5% | | |
GtreeBNT Co., Ltd. 22nd FL, Parkview Tower, 248 Jungjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-863, Republic of Korea
|
| | | | 19,583,333(3) | | | | | | | | | 13.6% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | | | | |
J.J. Finkelstein
|
| | | | 4,226,295(4) | | | | | | | | | 2.9% | | |
Allan L. Goldstein
|
| | | | 3,400,069(5) | | | | | | | | | 2.3% | | |
Joseph C. McNay
|
| | | | 7,898,705(6) | | | | | | | | | 5.5% | | |
Mauro Bove
|
| | | | 1,129,554(7) | | | | | | | | | * | | |
R. Don Elsey
|
| | | | 1,187,372(8) | | | | | | | | | * | | |
Alessandro Noseda
|
| | | | 310,000(9) | | | | | | | | | * | | |
All directors and executive officers as a group (6 persons)
|
| | |
|
18,151,996(10)
|
| | | | | | | | 12.5% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary(1)
($) |
| |
Bonus
($) |
| |
Option
Awards(2) ($) |
| |
All Other
Compensation(3) ($) |
| |
Total
($) |
| ||||||||||||||||||
J.J. Finkelstein, President and
|
| | | | 2020 | | | | | | 80,018 | | | | | | — | | | | | | 95,606 | | | | | | 3,360 | | | | | | 178,984 | | |
Chief Executive Officer
|
| | | | 2019 | | | | | | 81,528 | | | | | | — | | | | | | 103,523 | | | | | | 3,360 | | | | | | 188,411 | | |
Name
|
| |
Number of Shares
Underlying Unexercised Options (#) Exercisable |
| |
Number of Shares
Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Note
|
| ||||||||||||
Mr. Finkelstein
|
| | | | 125,000 | | | | | | 375,000 | | | | | | 0.30 | | | | | | 6/10/2030 | | | |
(1)
|
|
| | | | | 325,000 | | | | | | 325,000 | | | | | | 0.21 | | | | | | 5/15/2029 | | | |
(1)
|
|
| | | | | 200,000 | | | | | | — | | | | | | 0.64 | | | | | | 3/17/2023 | | | | | |
| | | | | 187,500 | | | | | | 62,500 | | | | | | 0.21 | | | | | | 7/16/2028 | | | |
(1)
|
|
| | | | | 500,000 | | | | | | — | | | | | | 0.21 | | | | | | 3/25/2021 | | | | | |
| | | | | 500,000 | | | | | | — | | | | | | 0.36 | | | | | | 6/30/2022 | | | | | |
| | | | | 150,000 | | | | | | — | | | | | | 0.28 | | | | | | 9/1/2027 | | | |
(1)
|
|
Plan Category
|
| |
Number of securities to
be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights (b) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) |
| |||||||||
Equity compensation plans approved by
security holders |
| | | | 11,951,250 | | | | | $ | 0.28 | | | | | | 4,148,966 | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 11,951,250 | | | | | $ | 0.28 | | | | | | 4,148,966 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Option
Awards ($)(1) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Allan Goldstein, Ph.D.
|
| | | | — | | | | | | 76,785 | | | | | | 90,000(2) | | | | | | 166,785 | | |
R. Don Elsey
|
| | | | — | | | | | | 47,803 | | | | | | — | | | | | | 47,803 | | |
Alessandro Noseda
|
| | | | — | | | | | | 38,424 | | | | | | — | | | | | | 38,424 | | |
Joseph McNay
|
| | | | — | | | | | | 47,803 | | | | | | — | | | | | | 47,803 | | |
Mauro Bove
|
| | | | — | | | | | | 38,424 | | | | | | — | | | | | | 38,424 | | |
|
Allan Goldstein, Ph.D.
|
| | | | 2,110,000 | | |
|
R. Don Elsey
|
| | | | 1,245,000 | | |
|
Alessandro Noseda
|
| | | | 400,000 | | |
|
Joseph McNay
|
| | | | 1,245,000 | | |
|
Mauro Bove
|
| | | | 1,175,000 | | |
Investor
|
| |
Note Principal
|
| |||
Essetifin S.p.A.
|
| | | $ | 400,000 | | |
J.J. Finkelstein
|
| | | $ | 10,000 | | |
Mauro Bove
|
| | | $ | 10,000 | | |
Allan L. Goldstein
|
| | | $ | 5,000 | | |
Investor
|
| |
Note Principal
|
| |||
Essetifin S.p.A.
|
| | | $ | 1,000,000 | | |
Joseph C. McNay
|
| | | $ | 25,000 | | |
J.J. Finkelstein
|
| | | $ | 25,000 | | |
Mauro Bove
|
| | | $ | 10,000 | | |
Allan L. Goldstein
|
| | | $ | 5,000 | | |
R. Don Elsey
|
| | | $ | 5,000 | | |
| | | | | | |
By Order of the Board of Directors
|
|
| | | | | | | | |
| | | | | | | /s/ Allan L. Goldstein, Ph.D. | |
| | | | | | | Allan L. Goldstein, Ph.D. | |
| | | | | | | Chairman of the Board | |
| | | |
RegeneRx Biopharmaceuticals, Inc.
|
| |||
| | | | By: | | |
J.J. Finkelstein, President
|
|
1 Year RegeneRX Biopharmaceutic... (CE) Chart |
1 Month RegeneRX Biopharmaceutic... (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions